<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01009216</url>
  </required_header>
  <id_info>
    <org_study_id>M10-505</org_study_id>
    <nct_id>NCT01009216</nct_id>
  </id_info>
  <brief_title>A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid</brief_title>
  <official_title>A Study to Evaluate the Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-384 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the cerebral spinal fluid (CSF) pharmacokinetics
      and the plasma/CSF pharmacokinetic/pharmacodynamic relationship of ABT-384 in healthy male
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)</measure>
    <time_frame>Days -1 through 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Pharmacokinetics (i.e., ABT-384 and possible metabolite levels) and Pharmacodynamics (i.e., biomarkers of drug effect)</measure>
    <time_frame>Days 1, 4 through 9</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ABT-384</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-384</intervention_name>
    <description>Doses will be administered daily for 5 days.</description>
    <arm_group_label>ABT-384</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age is between 18 and 55 years

          -  Judged to be in a condition of general good health based on the results of medical
             history, physical examination, vital signs, laboratory profile and a 12-lead ECG

        Exclusion Criteria:

          -  Use of protocol-prohibited medications within 2 weeks prior to study drug
             administration.

          -  Positive urine drug screen for non-prescribed drugs of abuse including alcohol.

          -  Receipt of any drug depot by injection within 30 days prior to study drug
             administration.

          -  Receipt of any investigational product within 6 weeks prior to study drug
             administration.

          -  History of significant sensitivity or allergy to any drug.

          -  History of drug or alcohol abuse.

          -  Positive test result for HAV, HBsAg, HCV or HIV.

          -  Donation or loss of 550 mL or more blood volume or receipt of any blood product within
             3 months prior to study drug administration.

          -  Contraindication for lumbar puncture (e.g., lumbar scoliosis, coagulopathy, infected
             skin at puncture site)

          -  Current enrollment in another clinical study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 23882</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <last_update_submitted>December 13, 2010</last_update_submitted>
  <last_update_submitted_qc>December 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gerard Marek, MD, PhD</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacology</keyword>
  <keyword>Drug Safety</keyword>
  <keyword>Phase 1 Clinical Trials</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

